Payment overview · 2025
General Payments
$459.05
27 reported records · 14 companies
Healthcare provider profile · identity verified
Eric Wayne Byrd, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HENDERSONVILLE, NC · NPI 1184699621
Verified facts
What the public records show
CMS Open Payments records show Eric Wayne Byrd, MD received $459.05 in general payments during 2025 across 27 reported records.
AstraZeneca Pharmaceuticals LP accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 372 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $143.01 | 31.1% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.33 | 13.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.55 | 7.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.27 | 6.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.91 | 5.4% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $24.13 | 5.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.03 | 4.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.58 | 4.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.73 | 4.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.34 | 4.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.10 | 3.9% | 1 | 2025 |
| Lucid Diagnostics Inc. | Unresolved — no canonical attribution shown | $17.13 | 3.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.87 | 3.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.07 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $459.05 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $52.04 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.07 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.07 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $39.00 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $36.19 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.55 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.27 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $24.13 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.58 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| NEXIUM Normalized: nexium |
Drug | AstraZeneca Pharmaceuticals LP | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 372 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 69 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
83 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 14 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
372 | 74 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
91 | 91 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
79 | 61 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 836 | 217 |
| Levothyroxine Sodium | Levothyroxine Sodium | 536 | 136 |
| Lisinopril | Lisinopril | 492 | 136 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 479 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 453 | 122 |
| Pantoprazole Sodium | Pantoprazole Sodium | 438 | 134 |
| Eliquis | Apixaban | 372 | 74 |
| Simvastatin | Simvastatin | 322 | 85 |
| Losartan Potassium | Losartan Potassium | 304 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 300 | 82 |
| Omeprazole | Omeprazole | 271 | 80 |
| Trazodone Hcl | Trazodone Hcl | 268 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 252 | 66 |
| Celecoxib | Celecoxib | 220 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 195 | 56 |
| Ezetimibe | Ezetimibe | 193 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 172 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 171 | 39 |
| Lorazepam | Lorazepam | 162 | 41 |
| Gabapentin | Gabapentin | 156 | 51 |
| Metformin Hcl Er | Metformin Hcl | 139 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 37 |
| Prednisone | Prednisone | 132 | 75 |
| Meloxicam | Meloxicam | 128 | 32 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 128 | 31 |
| Tramadol Hcl | Tramadol Hcl | 122 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 114 | 47 |
| Allopurinol | Allopurinol | 113 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 112 | 27 |
| Pregabalin | Pregabalin | 109 | 26 |
| Bupropion Xl | Bupropion Hcl | 106 | 28 |
| Potassium Chloride | Potassium Chloride | 104 | 30 |
| Sertraline Hcl | Sertraline Hcl | 101 | 33 |
| Clonazepam | Clonazepam | 99 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 99 | 34 |
| Montelukast Sodium | Montelukast Sodium | 94 | 27 |
| Atenolol | Atenolol | 93 | 21 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 91 | 91 |
| Finasteride | Finasteride | 86 | 22 |
| Furosemide | Furosemide | 86 | 33 |
| Alprazolam | Alprazolam | 85 | 20 |
| Synthroid | Levothyroxine Sodium | 83 | 20 |
| Famotidine | Famotidine | 81 | 24 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 79 | 61 |
| Warfarin Sodium | Warfarin Sodium | 79 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 75 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 39 |
| Nortriptyline Hcl | Nortriptyline Hcl | 72 | 18 |
| Farxiga | Dapagliflozin Propanediol | 69 | 14 |
| Metformin Hcl | Metformin Hcl | 69 | 19 |
| Irbesartan | Irbesartan | 66 | 18 |
| Trulicity | Dulaglutide | 63 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 62 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | suppressed |
| Carvedilol | Carvedilol | 59 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 57 | 16 |
| Spironolactone | Spironolactone | 55 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 15 |
| Ozempic | Semaglutide | 53 | suppressed |
| Myrbetriq | Mirabegron | 52 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 15 |
| Glimepiride | Glimepiride | 49 | 15 |
| Xarelto | Rivaroxaban | 48 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 45 | 12 |
| Chlorthalidone | Chlorthalidone | 45 | 12 |
| Diazepam | Diazepam | 44 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 40 | 32 |
| Mirtazapine | Mirtazapine | 40 | 12 |
| Enalapril Maleate | Enalapril Maleate | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 37 | 18 |
| Amoxicillin | Amoxicillin | 36 | 29 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 36 | 36 |
| Jardiance | Empagliflozin | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Colchicine | Colchicine | 35 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 30 |
| Ondansetron Odt | Ondansetron | 35 | 21 |
| Valsartan | Valsartan | 35 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | 11 |
| Temazepam | Temazepam | 33 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Olanzapine | Olanzapine | 29 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 28 | 26 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Estradiol | Estradiol | 27 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Azithromycin | Azithromycin | 22 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | 14 |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Eplerenone | Eplerenone | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Exemestane | Exemestane | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Xanax | Alprazolam | 12 | suppressed |
| Adderall | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Fluorouracil | Fluorouracil | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Trandolapril | Trandolapril | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $459.05 · 27 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, GVOKE HYPOPEN, Kerendia, MOUNJARO, NEXIUM, OTEZLA, Ozempic, PROLIA, REPATHA, REXULTI, Rybelsus, Senza, TRELEGY ELLIPTA, UBRELVY, XIFAXAN, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error